CELC — Celcuity Inc. stock price, charts and financials

Latest market price

92.49

+4.77+5.44%

Overview Short InterestFilings

CELCQT60Celcuity Inc.·NASDAQ

Overview Short InterestFilings

92.49+5.44%

News

Up 5.4% — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

Falling wedge — reversalHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MANE+5.29%$107.28 CAI-1.35%$16.10 DNTH+4.13%$110.40 DFTX+1.27%$42.32 ACAD+6.01%$27.15 ELVN+5.29%$61.11 EWTX+16.49%$44.71 DYN+2.89%$25.97

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	24.59%	Shs Outstand	48.77M	Perf Week	12.16%

Market Cap	4.51B	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-26.16%	Shs Float	29.91M	Perf Month	-14.82%

Enterprise Value	4.56B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	37.28%	Perf Quarter	-36.20%

Income	-177.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	7.36	Perf Half Y	-16.93%

Sales	0.00	P/B	83.53	EPS next Y	88.02%	ROA	-47.03%	Short Interest	11.15M	Perf YTD	-7.27%

Book/sh	1.11	P/C	31.11	EPS next 5Y	-	ROE	-244.61%	52W High	151.03 -38.76%	Perf Year	131.75%

Cash/sh	2.97	P/FCF	-	EPS past 3/5Y	-	ROIC	-49.49%	52W Low	38.93 137.58%	Perf 3Y	824.90%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.09% 6.29%	Perf 5Y	355.62%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-37.81%	Oper. Margin	0.00%	ATR (14)	6.01	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	12.31	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	49.14	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	12.31	EPS Q/Q	-12.79%	SMA20	-0.33%	Beta	0.20	Target Price	155.11

Payout	0.00%	Debt/Eq	1.93	Sales Q/Q	-	SMA50	-6.09%	Rel Volume	0.45	Prev Close	87.72

Employees	155	LT Debt/Eq	1.93	Earnings	Aug 13	SMA200	-11.19%	Avg Volume	1.58M	Price	92.49

IPO Date	Sep 19, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.73% -	Net Debt/EBITDA	-0.29	Volume	713,893	Change	5.44%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-15-26	Reiterated	Craig-Hallum	Buy	$171 → $178
Jul-15-26	Reiterated	HC Wainwright & Co.	Buy	$145 → $155
Jun-03-26	Reiterated	Craig-Hallum	Buy	$189 → $171
Jun-03-26	Reiterated	Wells Fargo	Overweight	$183 → $166
Jun-03-26	Reiterated	HC Wainwright & Co.	Buy	$185 → $145
Jun-02-26	Reiterated	Leerink Partners	Outperform	$155
May-28-26	Reiterated	Macquarie		$160
May-18-26	Reiterated	HC Wainwright & Co.	Buy	$165 → $185
May-15-26	Reiterated	Wells Fargo	Overweight	$126 → $183
May-04-26	Reiterated	Craig-Hallum	Buy	$141 → $189

Latest News

Aug-04-26

Aug-04-2605:45PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCglobenewswire.com

05:43PM

Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firmglobenewswire.com

Aug-03-26

Aug-03-2609:00PM

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violationsgurufocus.com

Aug-02-26

Aug-02-2605:27PM

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Lawbusinesswire.com

Jul-31-26

Jul-31-2611:22AM

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firmprnewswire.com

Jul-30-26

Jul-30-2610:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELCprnewswire.com

08:34AM

Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line TherapyBenzinga

08:30AM

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancerglobenewswire.com

Jul-29-26

Jul-29-2610:55AM

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firmglobenewswire.com

Jul-28-26

Jul-28-2607:50PM

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firmbusinesswire.com

05:31PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCglobenewswire.com

Jul-21-26

Jul-21-2604:58PM

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firmglobenewswire.com

02:31PM

Why CELC Stock Declined 15% in a Week Despite a Major FDA Winzacks.com

01:26PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCglobenewswire.com

Jul-20-26

Jul-20-2608:00PM

CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraudglobenewswire.com

Company

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	27	9	6	4	3	2	2	2	1
Research and Development	145	104	61	35	26	8	6	6	5
Other Operating Expense	0	0	-1	0	-1	0	0	0	0
Operating Income	-172	-113	-66	-39	-28	-10	-8	-8	-6
Interest Expense	17	10	5	2	1	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	12	8	1	0	0	0	0	0
Net Income Before Taxes	-177	-112	-64	-40	-30	-9	-7	-7	-6
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-177	-112	-64	-40	-30	-9	-7	-7	-6
Net Income From Continuing Operations	-177	-112	-64	-40	-30	-9	-7	-7	-6
Net Income	-177	-112	-64	-40	-30	-9	-7	-7	-6
EPS (Recurring)	-3.78	-2.83	-2.69	-2.68	-2.28	-0.89	-0.69	-0.74	-0.84
EPS (Basic, Before Extraordinaries)	-3.78	-2.83	-2.69	-2.68	-2.28	-0.89	-0.69	-0.74	-0.84
EPS (Diluted)	-3.78	-2.83	-2.69	-2.68	-2.28	-0.89	-0.69	-0.74	-0.84
EBITDA	-160	-101	-58	-38	-28	-9	-7	-8	-6
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	53	39	24	15	13	10	10	10	7
Market Capitalization	5,286	511	350	210	171	92	106	240	133
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	other: Former 10% owner	Jul 14 '26	Sale	102.50	3,100,000	317,750,000	442,940	Jul 16
Laing Lance G.	Chief Science Officer	Jun 02 '26	Option Exercise	9.89	1,000	9,890	1,251,000	Jun 04
Dalvey David	Director	May 04 '26	Sale	140.68	25,000	3,517,000	65,000	May 06
Buller Richard E	Director	May 04 '26	Option Exercise	5.10	9,000	45,900	15,760	May 06
Buller Richard E	Director	May 04 '26	Sale	140.46	9,000	1,264,181	6,760	May 06
Buller Richard E	Director	Mar 31 '26	Option Exercise	5.10	3,000	15,300	9,760	Apr 02
Buller Richard E	Director	Mar 31 '26	Sale	110.27	3,000	330,804	6,760	Apr 02
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,069	6,760	Dec 09
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,017	110,000	Nov 24
Buller Richard E	Director	Nov 20 '25	Sale	96.73	3,900	377,255	7,260	Nov 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.